Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ondansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.96 |
| ▸ | HTR3B | O95264 | 1/20 | 0.96 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.96 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.96 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.96 |
| ▸ | HTR2B | P41595 | 1/20 | 0.96 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.96 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.96 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.96 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.96 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.96 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ondansetron SCHEMBL27599152 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL25018 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29387592 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL7217414 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL157565 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL8153849 | 1.00 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL5123895 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL6186951 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29607040 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (S)-Ondansetron SCHEMBL25017 | 0.99 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1498216-A | Noval crystal and solvate forms of ondansetron hydrochloride and process for their preparation | ������ҩ��ҵ����˾ | 2004-05-19 | — | — | CN | claimed |
| EP-1339707-A2 | NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-09-03 | — | — | EP | claimed |
| US-20020107275-A1 | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2002-08-08 | — | — | US | claimed |
| WO-2002036558-A2 | NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-05-10 | — | — | WO | claimed |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-9913836-B2 | Anticholinergic neuroprotective composition and methods | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170087142-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-30 | — | — | US | disclosed |
| US-9561218-B2 | Anticholinergic neuroprotective composition and methods | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150231122-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2892514-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | Chase Pharmaceuticals Corporation (US) | 2015-07-15 | — | — | EP | disclosed |
| CN-104768540-A | Anticholinergic neuroprotective composition and methods | CHASE PHARMACEUTICALS CORP | 2015-07-08 | — | — | CN | disclosed |
| WO-2014039627-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
| CN-1498216-A | Noval crystal and solvate forms of ondansetron hydrochloride and process for their preparation | ������ҩ��ҵ����˾ | 2004-05-19 | — | — | CN | disclosed |
| EP-1339707-A2 | NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-09-03 | — | — | EP | disclosed |
| US-20020107275-A1 | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2002-08-08 | — | — | US | disclosed |
| WO-2002036558-A2 | NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107275-A1 | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation | SLC6A4, CYP3A43, CYP3A4 | HTR3A 10/4885CYP3A4 3/4885KCNH2 666/4885 |
| US-20170087142-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | HTR3A 226/4885CYP3A4 1086/4885KCNH2 3935/4885 |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | HTR3A 226/4885CYP3A4 1086/4885KCNH2 3935/4885 |
| US-20150231122-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | HTR3A 226/4885CYP3A4 1086/4885KCNH2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.